SpringWorks and GSK collaborate on myeloma combo testing

SpringWorks Therapeutics has joined forces with UK major GlaxoSmithKline (LSE: GSK) to evaluate SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with GSK’s investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), belantamab mafodotin (formerly GSK2857916), in patients with relapsed or refractory multiple myeloma.

“While significant advances have been made in treating multiple myeloma over the past decade, a significant unmet need remains for patients who have relapsed or are refractory to available treatments,” said Saqib Islam, Chief Executive Officer of SpringWorks Therapeutics, a spin-out from US pharma giant Pfizer (NYSE: PFE).

“We are delighted to enter into this agreement with GlaxoSmithKline, who also invested in our recent Series B financing, and we look forward to exploring the potential benefit of nirogacestat and belantamab mafodotin for multiple myeloma patients. With this collaboration, we are pleased to further expand on our strategy in building our targeted oncology portfolio with another industry leader,” he added,